|
Noxbox ltd.Became aware, through (e1), of an adverse event that occurred outside the united states involving a noxboxi nitric oxide delivery system.According to the reporter, during inhaled nitric oxide (ino) therapy the device unexpectedly powered off.The reporter stated that, although the device was connected to an external power source, the external power indicator was not illuminated and the device could not be powered back on.The device's external power supply was subsequently exchanged.Following the event, the device was opened and inspected by unauthorized hospital personnel.The reporter stated that a burning odor was observed originating from the power supply unit (psu) board.The reporter further stated that the patient expired following the event.At the time of this report, the relationship between the reported device issue and the patient's outcome has not been established.
|
|
The device was disassembled by the hospital after the event.The relationship of the reported issue to the patient's outcome cannot be established at this time.The incident is still under investigation.Per 21 c.F.R.803.16, a report or other information submitted by a reporting entity under this part, and any release by fda of that report or information, does not reflect a conclusion by the party submitting the report or by fda that the report or information constitutes an admission that the device or the reporting entity, caused or contributed to the reportable event.
|